IMSC - .63 This should help the potential of the company.
Implant Sciences Receives Patent for Narcotics and Explosives Particle Removal System
Company Continues to Build Patent Portfolio and Strengthen IP Position
WILMINGTON, MA, Mar 21, 2012 (MARKETWIRE via COMTEX) -- Implant Sciences Corporation (otcqb:IMSC) (pinksheets:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has been issued patent number 8,122,756 from the US Patent and Trademark Office. The patent, titled, "Narcotics and Explosives Particle Removal System," covers a method for removing particles from a target surface to increase sample collection.
Todd Silvestri, Implant Sciences' Vice President of Technology, commented, "Non-contact sample collection enables a wider range of deployment options for trace detection technologies. This invention is aimed at improving the collection efficiency of our non-contact sampling technologies."
Implant Sciences President and CEO Glenn D. Bolduc added, "This latest patent, the twelfth we have received, reaffirms Implant Sciences' commitment to being a true innovator in explosives and narcotics trace detection. New technologies that we have introduced include non-radioactive ionization, non-contact sampling, and automatic self-calibration. The breakthroughs made by our technology group continue to open new market opportunities for the Company and build shareholder value."
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor Contact:
Laurel Moody
646-810-0608
Email Contact |
